Network analyses of brain tumor multiomic data reveal pharmacological opportunities to alter cell state transitions
Open Access
- 1 February 2025
- journal article
- research article
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 11 (1) , 1-12
Abstract
Glioblastoma Multiforme (GBM) remains a particularly difficult cancer to treat, and survival outcomes remain poor. In addition to the lack of dedicated drug discovery programs for GBM, extensive intratumor heterogeneity and epigenetic plasticity related to cell-state transitions are major roadblocks to successful drug therapy in GBM. To study these phenomenon, publicly available snRNAseq and bulk RNAseq data from patient samples were used to categorize cells from patients into four cell states (i.e., phenotypes), namely: (i) neural progenitor-like (NPC-like), (ii) oligodendrocyte progenitor-like (OPC-like), (iii) astrocyte-like (AC-like), and (iv) mesenchymal-like (MES-like). Patients were subsequently grouped into subpopulations based on which cell-state was the most dominant in their respective tumor. By incorporating phosphoproteomic measurements from the same patients, a protein–protein interaction network (PPIN) was constructed for each cell state. These four-cell state PPINs were pooled to form a single Boolean network that was used for in silico protein knockout simulations to investigate mechanisms that either promote or prevent cell state transitions. Simulation results were input into a boosted tree machine learning model which predicted the cell states or phenotypes of GBM patients from an independent public data source, the Glioma Longitudinal Analysis (GLASS) Consortium. Combining the simulation results and the machine learning predictions, we generated hypotheses for clinically relevant causal mechanisms of cell state transitions. For example, the transcription factor TFAP2A can be seen to promote a transition from the NPC-like to the MES-like state. Such protein nodes and the associated signaling pathways provide potential drug targets that can be further tested in vitro and support cell state-directed (CSD) therapy.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM141891)
- My research is supported by the school of Pharmacy and Pharmaceutical Sciences at SUNY Buffalo
- Foundation for the National Institutes of Health (R35GM141891)
This publication has 69 references indexed in Scilit:
- Cell state‐directed therapy – epigenetic modulation of gene transcription demonstrated with a quantitative systems pharmacology model of temozolomideCPT: Pharmacometrics & Systems Pharmacology, 2023
- Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastomaCancer Cell, 2021
- Proteogenomic and metabolomic characterization of human glioblastomaCancer Cell, 2021
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent GlioblastomaJAMA Oncology, 2020
- The effect of decitabine on the expression and methylation of the PPP1CA, BTG2, and PTEN in association with changes in miR‐125b, miR‐17, and miR‐181b in NALM6 cell lineJournal of Cellular Biochemistry, 2019
- Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastomaActa Neuropathologica, 2018
- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the MicroenvironmentCancer Cell, 2017
- Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistryJournal of Neuro-Oncology, 2013
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesisCancer Cell, 2006